827025-43-4

Basic information

• Product Name: Benzoic acid, 4-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-
• CAS NO: 827025-43-4
• Molecular Formula: C14H12N2O4
• Molecular Weight: 272.26
• Mol File: 827025-43-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-(827025-43-4)
• EPA Substance Registry System: Benzoic acid, 4-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-(827025-43-4)

Safety Data

• Hazardous Substances Data: 827025-43-4(Hazardous Substances Data)

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 864291-34-9 4-(2-methylcarbamoyl-pyridin-4-yloxy)-benzoic acid methyl ester 
• 827025-42-3 C₁₆H₁₆N₂O₄ 

Downstream Products

• 284461-73-0 sorafenib 
• 864291-39-4 4-(2-methylcarbamoyl-pyridin-4-yloxy)-benzoic acid pentafluorophenyl ester 

Relevant articles and documents

Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways

Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.

BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula I or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase pathways, preferably by the raf kinase pathway, especially cancers, [FORMULA]